Houston regenerative medicine company to IPO, move toward more human trials

ready to list

FibroBiologics will IPO this week. Photo via Getty Images

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.”

O’Heeron was first exposed to the possibilities of fibroblasts as a means of regrowing discs in the spine. Since starting the company in 2008 as SpinalCyte, O’Heeron and FibroBiologics have organically written and filed more than 320 patents. Potential treatments go far beyond spinal surgery to include wound care, cancer, and multiple sclerosis.

According to O’Heeron, the goal in going public is to raise capital for human trials.

“We’ve had really fantastic results with animals and now we’re ready for humans,” he explained in September. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

FibroBiologics is growing with impressive speed. O’Heeron told us that he is hiring as quickly as he is able to find qualified scientists with the expertise to do the one-of-a-kind work required. The company opened a new lab last fall at the UH Technology Bridge, Newlin-Linscomb Lab for Cell Therapies. With its new status as a publicly traded company, FibroBiologics is primed to break even more ground.

FibroBiologics is opening a unique new lab at the University of Houston's Technology Bridge. Photo by Natalie Harms/InnovationMap

Houston regenerative medicine company opens new lab at UH

cell therapy innovation

Pete O’Heeron wants you to know that “Bohemian Rhapsody” was originally released as a B-side. What does this nugget about Queen have to do with regenerative medicine? For O’Heeron and his company, FibroBiologics, it means everything.

That’s because most scientists consider stem cells the A-side when it comes to the race to curing disease. But FibroBiologics has set its sights on fibroblasts. The most common cell in the body, fibroblasts are the main cell type in connective tissue.

“Everyone was betting on stem cells, and we started betting on fibroblasts,” says O’Heeron, who started the company in 2008 as SpinalCyte. “I think what we're going to see is that fibroblasts are going to end up winning, there are more robust, more that are lower cost cell, they have higher therapeutic values, higher immune modulation. They're just a better overall cell than the than the stem cells.”

Since a neurosurgeon and a dermatologist first introduced O’Heeron to the idea of using fibroblasts to regrow discs in the spine, the company has expanded its reach to include promising treatments for multiple sclerosis and cancer and in wound care. Imagine a world where doctors lay fibroblasts directly onto surgical incisions after surgery, cutting the time for healing in half.

FibroBiologics has organically written and filed more than 320 patents.

“It's quite a unique situation. I don’t think that in other areas of science that you have such a wide open area to go out and patent. It's just it was a brand new area nobody had been working on,” O’Heeron explains.

And soon, investors will be able to own a stake in the impressive work being forged in Houston. FibroBiologics, previously FibroGenesis, was formed in order to go public in a direct NASDAQ listing. The goal is to access the capital necessary to go to human trials. Earlier this year, the company also launched a crowdfunding campaign.

“We’ve had really fantastic results with animals and now we’re ready for humans,” says O’Heeron. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

With that in mind, the company just signed a deal with University of Houston’s Innovation Center. On Thursday, September 7, FibroBiologics will dedicate the Newlin-Linscomb Lab for Cell Therapies in the UH Technology Bridge. The new lab is named for former player and color commentator for the Houston Rockets, Mike Newlin and his wife, Cindy, as well as Pam and Dan Linscomb, a founding partner of Kuhl-Linscomb, one of the largest wealth management companies in Houston.

Other big local names newly attached to the company are astronaut Kate Rubins and Elizabeth Shpall, the director of the cell therapy laboratory at MD Anderson Cancer Center. Both have joined FibroBiologics as members of its scientific advisory board.

To fill the lab, O’Heeron says that he is adding to his team as quickly as he is able. The barrier is the fact that there are few, if any people in the world with the exact qualifications he’s seeking.

“Anytime you're breaking new scientific ground, you can't really just go out and recruit someone with that background because it really doesn't exist,” he says. But he is willing to teach and challenge scientists who are the right fit, and is hoping to expand the team in the new lab.

But like Queen did in 1975, FibroBiologics is pioneering a category of its own. And that’s something worth betting on.

A Houston research team is studying the effects of regenerative medicine on hearts. Photo via TMC.org

Innovative Houston lab works with 'ghost hearts' to study impact of regenerative medicine

stem cell magic

Ask any high achiever and they’ll tell you — failure is the path to success.

As Camila Hochman-Mendez puts it, “I’m like Thomas Edison, right? I know a thousand ways of how not to create a lightbulb.” But she’s not really talking about electricity. Hochman-Mendez is director of Regenerative Medicine Research and the Biorepository Core at Texas Heart Institute.

Hochman-Mendez follows another pioneering woman in the role, Doris Taylor. The younger scientist took on the prime job when Taylor left in 2020. By then, Hochman-Mendez had been at The Texas Heart Institute for three years, moving from research scientist to assistant director in just four months.

Regenerative Medicine is every bit as exciting as it sounds. At Hochman-Mendez’s lab, her team creates ghost hearts — organs from which all cells are scrubbed, leaving collagen, fibronectin, and laminin in the shape of the formerly beating ticker. The goal is to use the decellularized organs as protein scaffolds that, once injected with stem cells, will once again contract and pump blood.

Hochman-Mendez cautions that we are still years away from that point, but her lab is working hard to get there.

“The ultimate goal is to develop functional hearts that can be used for transplant,” says Hochman-Mendez.

Those hearts would be made from the patient’s own cells, avoiding organ rejection, which the scientist says is essentially trading one disease for another. But she is realistic about that fact that there are many barriers to her success.

“It does come with a lot of technical challenges,” she says.

These challenges include the simple number of cells that billions, and potentially hundreds of billions of cardiomyocytes are needed to recreate a human heart. The necessary protocols, Hochman-Mendez explains, are extremely costly and labor intensive.

It also takes 60 days for the cells to reach a maturity at which they can function. The lab recently received a pair of grants targeted at creating bioreactors that can be reliable for at least those 60 days.

The third major issue facing the Regenerative Medicine lab is contamination.

“It needs to be very sterile,” says Hochman-Mendez. “It needs to be so clean that if you have one tiny bacteria there, you’re screwed.”

Fortunately, the scientist says that her favorite hobby is computer programming. She and a physician colleague have created a robotic arm that can help to prevent the contamination that often stemmed from humans manually injecting stem cells into the decellularized organs.

This not only works towards solving the contamination problem, it also allows the team to more accurately distribute the cells that they add, using an injection map. To that end, she is producing a three-dimensional model of a protein scaffold that will allow her team and other scientists in the field of regenerative medicine to understand how the cells really disperse when they inject them.

When will her lab produce working hearts?

“I try to be very conservative on timing,” she says.

She explains that it will take significant leaps in technology to make a heart mature to the level at which it’s usable for an adult body in 60 days.

“That’s magic and I don’t believe in magic,” she says, but adds that she hopes to have a prototype ready to be tested in five years.

Hochman-Mendez does this all with a small team of nine researchers, most of whom happen to be female.

“The best candidates are the ones that I select," she says. "The majority are females. I think it’s a mix of trying to be very unbiased, but I usually don’t even look at the name before looking at the CV to preselect the people that I interview.”

And together, Hochman-Mendez are making medical history, one success-spawning failure at a time.

Camila Hochman-Mendez is director of Regenerative Medicine Research and the Biorepository Core at Texas Heart Institute. Photo via texasheart.org

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

Houston biopharma company launches equity crowdfunding campaign

money moves

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Celltex is looking into using stem cells to treat COVID-19, and the Houston biotech company just got the green light to go to trials. Photo courtesy of Celltex

Houston biotech company gets FDA greenlight to move forward with COVID-19 stem cell treatment

coronavirus cure?

A Houston-based biotech company announced last week that it has gotten the approval it was seeking from the U.S. Food and Drug Administration to continue testing its COVID-19 treatment that uses stem cells.

Celltex has received approval from its Investigational New Drug application, or IND, to look into stem cells — specifically Autologous Adipose Tissue-Derived Mesenchymal Stem Cells, or AdMSCs — and their effect on COVID-19 patients.

"The FDA's approval of our IND is not only a critical milestone for Celltex, but also for everyone who has been affected by COVID-19," says David G. Eller, Celltex chairman and CEO. "I am optimistic that our findings will result in favorable outcomes that will improve lives today and for generations to come."

Celltex has been in the stem cell business for nearly a decade and has treated patients with debilitating diseases like multiple sclerosis, Parkinson's, rheumatoid arthritis, and more. Eller says he's been considering how Mesenchymal Stem Cells, or MSCs, could be used amid the pandemic.

"Throughout the entire pandemic, MSCs have shown promise for combatting symptoms and complications associated with COVID-19, and as the nation's leading commercial MSC banking and technology company, Celltex has the unique ability to transition these initial findings into a clinical trial," Eller says.

The FDA clearance will allow for a phase two trial "that will evaluate the safety and prophylactic efficacy of AdMSCs against COVID-19," according to the release. There will be 200 patients across multiple centers that will be involved in the placebo-controlled study.

Celltex offices out of the Galleria area and has laboratory operations of its wholly-owned Mexican subsidiary are located in Hospital Galenia in Cancún, Quintana Roo, Mexico. Last year, Celltex planned an expansion into Saudi Arabia and also has a presence in Europe.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

10+ can't-miss Houston business and innovation events for April

WHERE TO BE

From pitching competitions to expert speaker summits, April is filled with opportunities for Houston innovators.

Here's a roundup of events you won't want to miss out on so mark your calendars and register accordingly.

Note: This post may be updated to add more events.

April 4 — Mission Control: Texas’ Leadership in Space, Technology, and Innovation 

Since its inception, the space industry has expanded across Texas and grown beyond scientific exploration into a tableau on which the terrestrial set have placed bets related to tourism, mining, communications, healthcare, food science, national security, technical innovations across all industries, and even human habitation beyond earth. The Texas Lyceum’s 2024 Public Conference (PubCon) will explore these opportunities and the journey to realize the promise of space and beyond for Texas and the nation.

Throughout the event, an expected 300 industry leaders and Texas legislators and staffers will participate in thought provoking discussions to inform our stakeholders and state leaders on the trajectory, challenges and opportunities in the Space Economy.

This event starts Thursday, April 4, from 2:30 to 9:30 pm at the Thompson Hotel. Click here to register.

April 4-6 — 2024 Rice Business Plan Competition

Hosted and organized by the Rice Alliance for Technology and Entrepreneurship, which is Rice University's internationally-recognized initiative devoted to the support of entrepreneurship, and Rice Business, the Rice Business Plan Competition offers an educational program mirroring real-world experience through this multi-day event for student startups from across the world.

In total, more than $1 million in investment and cash prizes are expected to be awarded at the 2024 Rice Business Plan Competition. Every single startup will walk away with at least $950 in cash prizes, no matter where they place in the competition.

The Elevator Pitch event is open to the public and on Thursday, April 4, from 6 to 9 pm at Jones Graduate School of Business. Click here to register.

April 6 — 12th Annual Houston Global Health Collaborative Conference

This meeting is an annual gathering of interdisciplinary professionals and students with a passion for global health innovation and advancement. This year's Conference Theme is Global Health Diplomacy: Shaping Policies for Health Impact and will feature subthemes of vaccine diplomacy, global surgery, the prevalence of non-communicable diseases, and the global nutrition crisis. Clinicians, researchers, healthcare workers, policymakers, and students across any field who are interested in global health are especially encouraged to attend.

This event is Saturday, April 6, from 7:45 am to 7 pm at the University of Houston College of Medicine. Click here to register.

April 10 — Bayou City Bio Pulse

Check out a showcase of life sciences in The Woodlands. This event will feature a vendor exhibition, presentations from business, academic and community development leaders, and a panel discussion on The Woodlands’ life sciences ecosystem. Spanning across five sites totaling over 80 acres, The Woodlands Innovation District is positioned to meet the needs of companies focused on in-house manufacturing (from biopharma to industrial biology), as well as contract development manufacturing organizations (CDMOs).

This event is Wednesday, April 10, from 8 am to 12 pm at the Woodlands Towers. Click here to register.

April 18 — Energy Underground: All Things Hydrogen

The Energy Underground is a group of professionals in the Greater Houston area that are accelerating the Energy Transition. Come together to learn and support each other's work in advancing the Energy Transition: make industry contacts, secure financing, share deals, recommend talent looking to enter the energy workforce, and anything else that leads to bigger, better energy companies.

This event is Thursday, April 18, from 12 to 1:30 pm at the Cannon West Houston. Click here to register.

April 19 — Build Day x Tour: Houston Hackathon

A partnership between ACT House, a human analytics leader, and Tech Equity Collective, a Google Initiative driving black innovation in tech formed an exciting new accelerator. Participants will build their own startup team, collaborate on ideas, and sprint on real work. The first place winning team will receive $10,000, the second place team will recieve $5,000 and the third place team will get $2,500.

This event is Friday, April 19, at 4 pm until April 20 at 4 pm. Click here to register.

April 21 — The Energy Corridor District's Earth Day Celebration

Come out for a day of fun and environmental awareness. Get hands-on and contribute to a communal art piece that symbolizes a collective commitment to Mother Earth. Pick up a brush or a marker and add your creativity to the canvas.

Take a moment to learn how the world's top energy companies are contributing to a more sustainable future. Get inspired and pick up some tips for your own eco-journey

This event is Sunday, April 21, from 1 to 4 pm at Terry Hershey Park. Click here to register.

April 22 — EO4Energy Workshop

The Geological Remote Sensing Group (GRSG) Americas, in partnership with the University of Houston, invites you to a workshop focusing on the role of Earth Observation (EO) and remote sensing in the Energy Industry.

As the industry moves towards sustainability, driven by Environmental, Social, and Governance (ESG) considerations, the significance of EO and remote sensing continues to grow. This workshop will encompass insightful case studies, introduce emerging technologies, and present advanced methodologies. Participants will engage with a diverse group of professionals from the energy, space, academic, and government sectors.

This event begins Monday, April 22, at 8 am at Hilton University of Houston. Click here to register.

April 25 — 2024 PIDX International US Spring Conference

In this industry event, explore the intersection of AI and Digital Standards. All experienced speakers across industries are invited to contribute articles, share use cases and theories, and connect with attendees from the Energy Industry.

The accumulated knowledge shared at the event will guide the forthcoming phase of PIDX Standards Development tailored for the Energy Industry.

This event begins Thursday, April 25, at 8 am at 501 Westlake Park. Click here to register.

April 26 — StartupLaunch USA: Ignite Your Entrepreneurial Journey

This is an immersive online learning experience tailored for aspiring entrepreneurs looking to kickstart their startup ventures in the United States. This event provides participants with the essential knowledge, skills, and resources needed to navigate the complexities of launching and scaling a successful business.

Through a series of interactive workshops, expert-led seminars, and practical case studies. Participants will learn how to develop innovative business ideas, validate market opportunities, and create viable business models that resonate with target audiences.

This event is Friday, April 26, from 1 to 6 pm at Museum of Natural Science. Click here to register.

April 27 — World Youth Foundation: STEAM Innovation Incubator

WYF's STEAM Innovation Industry Pathways, or SIIP, is a youth out-of-school-time monthly program designed to bridge the gap between academic learning, industry, and digital skilling.

Open to youth ages 6 to 24, SIIP is not your typical program—it's a gateway to a world of metaskilling, offering a dynamic range of skills from design thinking, strategic project management, soft skills development, digital skills development, and industry application.

This event is Saturday, April 27, from 10 am to 1:30 pm at Sunnyside Health and Multi-Service Center. Click here to register.


Report: Here's how Houston ranks in terms of its gender pay gap

by the numbers

It's 2024 and women are still making less money than men, thus keeping the unfortunate reality of the wage gap alive. But at least in Houston, the wage gap isn't as bad as other Texas cities, according to a new earnings study by Chamber of Commerce.

Houston ranked No. 142 on the list, which examined earnings for full-time workers in 170 of the most populous cities in the United States.

The study found that, in 2024, men in Houston are currently making $4,474 more than women — a figure that's significantly lower than the national wage gap, which is a little over $11,000.

The U.S. city with the worst gender pay gap is none other than Frisco, a Dallas suburb. Men in Frisco are currently making a staggering $52,216 more than women, which is more than $12,000 more than the gap in 2023.

Also in North Texas, McKinney remained in the No. 5 spot for the second consecutive year. McKinney men make $24,568 more than women, which is a $4,400 decrease year-over-year. Plano's gender wage gap has worsened since 2023: The Dallas suburb is now listed among the top 10 worst pay gaps in the U.S., climbing to No. 6. The study says the Plano's wage gap is now $23,415, or nearly $2,300 more than last year.

Statewide gender pay gap

Chamber of Commerce found that Texas' gender pay gap has increased since last year; The 2023 study found that women made nearly $11,000 less than men, and that discrepancy has widened in 2024 to nearly $12,000.

However, Texas' ranking has improved 10 spots from No. 29 last year to No. 19 this year.

For added context, New Hampshire has the No. 1 worst pay gap in the nation, with men making over $18,000 more than women.

Other Texas cities that earned spots in the report are:

  • No. 20 – Amarillo
  • No. 22 – Laredo
  • No. 24 – Austin
  • No. 30 – Corpus Christi
  • No. 31 – Pasadena
  • No. 33 – Irving
  • No. 52 – Lubbock
  • No. 59 – El Paso
  • No. 65 – Grand Prairie
  • No. 81 – Fort Worth
  • No. 118 – Dallas
  • No. 121 – San Antonio
  • No. 125 – Arlington
  • No. 167 – Brownsville
  • No. 168 – Garland

------

This article originally ran on CultureMap.

3 Houston innovators to know this week

who's who

Editor's note: Welcome to another Monday edition of Innovators to Know. Today I'm introducing you to three Houstonians to read up about — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.

Sean Kelly, CEO and co-founder of Amperon

Amperon CEO Sean Kelly joins the Houston Innovators Podcast to share his company's growth and expansion plans. Photo via LinkedIn

The technology that Amperon provides its customers — a comprehensive, AI-backed data analytics platform — is majorly key to the energy industry and the transition of the sector. But CEO Sean Kelly says he doesn't run his business like an energy company.

Kelly explains on the Houston Innovators Podcast that he chooses to run Amperon as a tech company when it comes to hiring and scaling.

"There are a lot of energy companies that do tech — they'll hire a large IT department, they'll outsource a bunch of things, and they'll try to undergo a product themselves because they think it should be IP," he says on the show. "A tech company means that at your core, you're trying to build the best and brightest technology." Continue reading.

Amanda Burkhardt, CEO of Phiogen

Spun out of Baylor College of Medicine, Phiogen was selected out of 670 companies to pitch at SXSW earlier this month. Photo via LinkedIn

A new Houston biotech company won a special award at the 16th Annual SXSW Pitch Award Ceremony earlier this month.

Phiogen, one of 45 companies that competed in nine categories, was the winner for best inclusivity, much to the surprise of the company’s CEO, Amanda Burkhardt.

Burkhardt tells InnovationMap that while she wanted to represent the heavily female patient population that Phiogen seeks to treat, really she just hires the most skilled scientists.

“The best talent was the folks that we have and it ends up being we have three green card holders on our team. As far as ethnicities, we have on our team we have Indian, African-American, Korean, Chinese Pakistani, Moroccan and Hispanic people and that just kind of just makes up the people who helped us on a day-to-day basis,” she explains. Continue reading.

Mielad Ziaee, 2023-2024 All of Us Research Scholar

Mielad Ziaee, a 20-year-old student at the University of Houston, was tapped for a unique National Institutes of Health program. Photo via UH.edu

A Houston-area undergraduate student has been tapped for a prestigious national program that pairs early-career investigators with health research professionals.

Mielad Ziaee was selected for the National Institutes of Health’s 2023-2024 All of Us Research Scholar Program, which connects young innovators with experts "working to advance the field of precision medicine," according to a statement from UH. Ziaee – a 20-year-old majoring in psychology and minoring in biology, medicine and society who plans to graduate in 2025 — plans to research how genomics, or the studying of a person's DNA, can be used to impact health.

“I’ll be one of the ones that define what this field of personalized, precision medicine will look like in the future,” Ziaee said in a statement. “It’s exciting and it’s a big responsibility that will involve engaging diverse populations and stakeholders from different systems – from researchers to health care providers to policymakers.” Continue reading.

View All Listings